Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic
COPENHAGEN, Denmark, September 20, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the board of directors has appointed Luc Debruyne as an observer to the board with the intent to nominate him for election to the board at the ordinary general meeting in March 2023, where he following the board’s constitution is expected to assume the chairmanship after Gerard van Odijk, who will step down after having served for 15 years on the board.
Luc Debruyne is former President Global Vaccines at GSK, a role he held for the last six years of his 27-year long tenure with the company, where he was a member of GSK’s Corporate Executive Team. He is currently Professor of Practice at the University of Leuven, Faculty of Medicine, Biomedical Sciences Group and serves as non-executive director of the boards of University Hospitals UZ Leuven and Fund Plus. He is furthermore member of the Institutional Advisory Board at VIB, the Life Sciences Board at Greenlight Biosciences Inc, and is Strategy Advisor to the CEO and Chair of the Portfolio Strategy and Management Board of CEPI. Luc Debruyne is also highly regarded as an active contributor and advisor in the global health arena with a focus on R&D and access.
Gerard van Odijk, chairman of the board said: “I am pleased to welcome Luc on the board and look forward to our collaboration until my departure as chairman next year. Luc’s wealth of industry experience combined with strong leadership, global health experience and a proven track record of commercial launches will be a significant contribution to the board and to Bavarian Nordic in our continued endeavor to create one of the largest pure play vaccine companies.”
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 37 / 2022
Attachment
